Patent ID: 6602521
Filing Date: 2003-08-05
Classification: A61J,A61K

Abstract:
A multiplex active agent delivery system in the form of a tablet suitable for oral administration, comprising two, three or four immediate release compartments wherein each immediate release compartment contains an active agent selected from the group consisting of diltiazem, trapidil, urapidil, benziodarone, dipyrudamole, isosorbide mononitrate, lidoflazine, non-steroidal anti-inflammatory drugs (NSAIDs), steroidal anti-inflammatory drugs, acetaminophen, aldosterone, alprenolol, amitryptyline, aspirin, beclomethasone, diproprionate, bromocriptine, butorphanol tartrate, chlormethiazole, chlorpheniramine, chlorpromazine HCl, cimetidine, codeine, cortisone, cyclobenzamine HCl, desmethylimipramine, dextropoxyphene, dihydroergotamine, diltiazem HCl, dobutamine HCl, domperidone, dopamine HCl, doxepin HCl, epinephrine, ergoloid mesylates, ergotamine tartrate estradiol, ethinylestradiol, flunisolide, fluorouracil, flurazepam HCl, 5-fluoro-21deoxyuridine, furosemide, glipizide, glyburide, glyceryl trinitrate, guanethidine sulfate, hydralazine HCl, indoramin, isoethorine HCl, isoethrine mesylate, isoprenaline, isoproterenol sulfate, isosorbide dinitrate, levodopa, lidocaine HCl, lignocaine, lorcainide, meperidine HCl, 6-mercaptopurine, metaproterenol sulfate, methoxamine HCl, methylphenidate, methyepreonisolone, methyltestosterone mesylate, metoclopramide, metoprolol tartrate, morphine sulfate, nalbuphine HCl, naloxone HCl, neostigmine, nifedipine, nitrendipine, nitroglycerin, norepineohrine bitartate, norethindore, nortriptylen HCl, oxprenolol, oxyphenbutzone, penicillamine, pentazocine HCl, pentazcine lactate, pentobarbital, petnidine, phenacetin, phentolamine HCl, phentolamine mesylate, phenylephrine HCl, phenylephrine bitartrate, phenytoin, pindolal, prazosin, prednisone, progesterone, propoxyphene HCl, propoxyphene napsylate, propranolol HCl, quinidine, reserpine, ritodrine HCl, salicyamide, salbutamol, secobarbital, testosterone, terbutaline, timolol maleate, tolbutamide, and verapamil HCl, and an extended release polymer outer layer which substantially envelops the immediate release compartments, wherein the tablet is scored such that when the active agent delivery system is separated along the score into sections, each of the sections contains an immediate release compartment within an extended release polymer outer layer, and wherein the active agent delivery system is not an osmotic pump, and wherein the active agents exhibit the following in vitro dissolution profile when measured in a type 1 dissolution apparatus (paddle) according to U.S. Pharmacopoeia XXII at 37Â° C.Â±0.5Â° C. in deionized water at 75 rotations per minute:(a) from about 10% to about 75% of said active agent is released between 1 hour and 5 hours of measurement in said apparatus; and, (b) no less than about 90% of said active agent is released after 6 hours of measurement said apparatus.